The Open Source Drug Discovery (OSDD) strategy uses an open innovation model with a porous-walled funnel to facilitate the free flow of ideas and projects. It brings in more contributors to look at projects and enables redundancies and parallelization. OSDD acts as a facilitator to marry academic and delivery-focused approaches and provides expertise, discovery platforms, and coordination of activities from both individual and centrally coordinated projects. OSDD has established multiple platforms for drug discovery including compound management, screening, target validation, and mechanistic studies. It has an extensive portfolio involving over 180 principal investigators from over 100 institutions working on projects ranging from whole cell screening to structure-based drug design.
Dr. Edward Kai-Hua Chow, JALA Associate Editor/Asia and National University of Singapore, shares his SLAS2013 JALA and JBS Authors Workshop presentation. Learn more about these leading peer-reviewed journals, and then see Ed's tips for publication beginning on slide 16.
A Talk delivered at both UNC Chapel Hill and Drexel University
There is an increasing availability of free and open access resources for scientists to use on the internet. Coupled with the increasing availability of Open Source software tools we are in the middle of a revolution in data availability and tools to manipulate these data. However, freedom costs and in many cases the cost is quality. ChemSpider is a free access website for chemists built with the intention of providing a structure centric community for chemists. As an aggregator of chemistry related information from many sources, at present over 21.5 million unique chemical entities from over 150 separate data sources, ChemSpider has taken on the task of both robotically and manually curating publicly available data sources. This presentation will provide an overview of the issue of quality in many chemistry-related databases, approaches to cleaning up the data and how a curated platform can become the centralized hub for resourcing information about chemical entities. This includes experimental and predicted properties, analytical data, publications, suppliers and integrated databases. I will detail three efforts :1) the curation of chemistry on Wikipedia 2) an examination of structure integrity on the FDA Daily Med website, a web site of medication content and labeling as found in medication package inserts 3) recognizing chemical names in documents and providing a platform for structure-based searching of Open Access chemistry literature.
ChemSpider is an online database of over 20 million chemical structures assembled from almost a hundred data sources including chemical and screening library vendors, publicly accessible databases and resources, commercial databases and Open Access literature articles. Such a public resource provides a rich source of ligands for the purpose of virtual screening experiments. These can take many forms. This work will present results from two specific types of studies: 1) Quantitative Structure Activity Relationship (QSAR) based analyses and 2) In-silico docking into protein receptor sites. We will review results from the application of both approaches to a number of specific examples using the software outlined below.
The QSAR analyses utilize the ChemModLab environment which is a free, web-based toolbox for fitting and assessing quantitative structure-activity relationships. Its elements include a cheminformatics front end to supply molecular descriptors, a set of statistical methods for fitting models, and methods for validating the resulting model. Five molecular descriptor sets are used with 16 math modeling methods to give a total of 80 QSAR models. The input is a file of compounds and a text file for biological activity.
The in-silico docking experiments are conducted using a combination QSAR/Docking approach using the SimBioSys eHITS and Lasso software programs. The docking procedure allows for the screening of a complete molecular database to obtain the correct binding poses and estimated binding affinities. The ligand based screening tool utilizes a novel conformation independent 3D QSAR descriptor, ideally suited for scaffold hopping.
The Role of Retention Time in Untargeted MetabolomicsJan Stanstrup
This presentation is about why retention time is important in untargeted metabolomics and how it can be used to identify compounds without having access to standards.
Dr. Edward Kai-Hua Chow, JALA Associate Editor/Asia and National University of Singapore, shares his SLAS2013 JALA and JBS Authors Workshop presentation. Learn more about these leading peer-reviewed journals, and then see Ed's tips for publication beginning on slide 16.
A Talk delivered at both UNC Chapel Hill and Drexel University
There is an increasing availability of free and open access resources for scientists to use on the internet. Coupled with the increasing availability of Open Source software tools we are in the middle of a revolution in data availability and tools to manipulate these data. However, freedom costs and in many cases the cost is quality. ChemSpider is a free access website for chemists built with the intention of providing a structure centric community for chemists. As an aggregator of chemistry related information from many sources, at present over 21.5 million unique chemical entities from over 150 separate data sources, ChemSpider has taken on the task of both robotically and manually curating publicly available data sources. This presentation will provide an overview of the issue of quality in many chemistry-related databases, approaches to cleaning up the data and how a curated platform can become the centralized hub for resourcing information about chemical entities. This includes experimental and predicted properties, analytical data, publications, suppliers and integrated databases. I will detail three efforts :1) the curation of chemistry on Wikipedia 2) an examination of structure integrity on the FDA Daily Med website, a web site of medication content and labeling as found in medication package inserts 3) recognizing chemical names in documents and providing a platform for structure-based searching of Open Access chemistry literature.
ChemSpider is an online database of over 20 million chemical structures assembled from almost a hundred data sources including chemical and screening library vendors, publicly accessible databases and resources, commercial databases and Open Access literature articles. Such a public resource provides a rich source of ligands for the purpose of virtual screening experiments. These can take many forms. This work will present results from two specific types of studies: 1) Quantitative Structure Activity Relationship (QSAR) based analyses and 2) In-silico docking into protein receptor sites. We will review results from the application of both approaches to a number of specific examples using the software outlined below.
The QSAR analyses utilize the ChemModLab environment which is a free, web-based toolbox for fitting and assessing quantitative structure-activity relationships. Its elements include a cheminformatics front end to supply molecular descriptors, a set of statistical methods for fitting models, and methods for validating the resulting model. Five molecular descriptor sets are used with 16 math modeling methods to give a total of 80 QSAR models. The input is a file of compounds and a text file for biological activity.
The in-silico docking experiments are conducted using a combination QSAR/Docking approach using the SimBioSys eHITS and Lasso software programs. The docking procedure allows for the screening of a complete molecular database to obtain the correct binding poses and estimated binding affinities. The ligand based screening tool utilizes a novel conformation independent 3D QSAR descriptor, ideally suited for scaffold hopping.
The Role of Retention Time in Untargeted MetabolomicsJan Stanstrup
This presentation is about why retention time is important in untargeted metabolomics and how it can be used to identify compounds without having access to standards.
Once again, The Candidate are extremely excited to announce our latest piece of research. Following on from the Women in Digital research we wanted to further our knowledge of the digital sector by researching the current state of management in the ever growing digital sector.
Our report looks into how managers are ranked for their own abilities and then comparing this to how managers are ranked from an employee’s perspective. To do this we spoke to 150 managers and 150 employees to cover specific areas and from this we’ve picked up on the following results:
- Only 53% of managers in the digital sector ranked their own abilities as ‘good’, ‘really good’, or ‘excellent’, with the rest ranking their abilities as ‘average’ or ‘below average’ – suggesting a lack of confidence in their managerial skills
- Good communication is the quality that both managers and employees working in digital cited as the most important. Approachability was highly valued by 46% of employees, but just 24% of managers agreed
- 27% of employees cited that being highly skilled, was a in the top 3 qualities of being a manger
- Surprisingly 3% of employees started that having a bad manager would have no effect on the team whereas every manager agreed that being a bad manager would affect the whole team
Our very own Brian Matthews states why this research is important for the development of the industry.
‘The industry now employs 1.46m people across the country, and is estimated to grow by 5.4% by 2020. In order to develop the industry successfully and help it grow at its expected pace, we need the help of good managers who can nature the talent’
We’re hoping that our report helps to reveal some issues which may have an effect on the digital sector.
For the full video of this presentation, please visit:
http://www.embedded-vision.com/industry-analysis/video-interviews-demos/overcoming-barriers-consumer-adoption-vision-enabled-produc
For more information about embedded vision, please visit:
http://www.embedded-vision.com
John Feland, CEO and Founder of Argus Insights, presents the "Overcoming Barriers to Consumer Adoption of Vision-enabled Products and Services" tutorial at the May 2015 Embedded Vision Summit.
Visual intelligence is being deployed in a growing range of consumer products, including smartphones, tablets, security cameras, laptops (especially with Intel’s RealSense push), and even smartwatches. The demos are always cool. But does vision work for regular consumers? Do consumers see vision as a value add or just another feature to be ignored?
In this talk, John investigates the best and worst of consumer product embedded vision implementations as told by real consumers, based on Argus Insights’ extensive portfolio of consumer data. John examines where current products fall short of consumers’ needs. And, he illuminates successful implementations to show how their vision capabilities create value in the lives of consumers. Case studies will include examples from Dropcam, Intel RealSense, HTC’s M8, and vision-enabled drones such as the DJI Phantom 2 Vision+.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
The new role of R&D and process for new products in pharmaceutical industry has been established
Productivity increase of Orion R&D within 6 years by :
-Classification of partners
-Partnering and outsourcing models in use
Need of reliable key metrics to value R&D investment and boost the future growth of the company
In silico 360 Analysis for Drug DevelopmentChris Southan
Introduction:
Consequent to a memorandum of understanding between the Karolinska Institutet and the International Union of Basic and Clinical Pharmacology (IUPHAR) in 2018 a report on academic drug development, including guidelines (ADEV) has been drafted [1]. As part of this exercise, we conceived a triage for comprehensive informatics profiling around the compound, target, disease axis. We have termed this “in slico 360” (INS360) the aim of which was to support ADEV teams since they may lack either internal expertise or external support to do this on their own. Indeed, some past SciLifeLab Drug Discovery and Development Platform projects had been halted because of overlooked competitive impingements or insufficient target validation evidence.
Methods
We assessed the current database landscape, mostly public but including commercial, for potential utility for INS360. We were guided primarily by content coverage, usability, and reputation. We also explored some open property prediction resources for assay interference and toxicological inferences.
Results:
As a first-stop-shop, we selected the IUPHAR/BPS Guide to PHARMACOLOGY with ~900 ligand-target relationships captured via expert curation of journal papers Moving up in scale we evaluated ChEMBL at 1.8 million compounds with 1.1 million assay descriptions and 7,000 targets. With yet another jump we could search the patent corpus with 18 million extracted compounds in SureChEMBL. We explored PubChem that integrates these three with over 500 other sources linked to 96 million compounds, BioAssay results and connectivity into the NCBI Entrez system. The final jump in scale for document-to-chemistry navigation was represented by SciFinder with 155 million structures. On the target side, 360-exploration has the need to encompass literature, structure, genetic variation, splicing, interactions, and disease pathways. From their UniProt links, both GtoPdb and ChEMBL provide these entry points. Navigating genetic association data in support of target validation was enabled by the OpenTargets portal and the GWAS Catalog. We also fount servers that could produce prediction scores from chemical structures for a range of features important for de-risking development.
Conclusion:
This work scoped out initial resource choices for the INS360. We propose that not only ADEV operations but essentially any pharmacology research team has much to gain from this approach and many potential pitfalls can consequently be avoided when approaching key checkpoints, such as preparing a publication. However, support may be needed for both institutions and teams to get the best out of these complex and feature-rich databases.
[1] Southan C, (2019) Towards Academic Drug Development Guidelines, ChemRxiv pre-print no. 8869574
Once again, The Candidate are extremely excited to announce our latest piece of research. Following on from the Women in Digital research we wanted to further our knowledge of the digital sector by researching the current state of management in the ever growing digital sector.
Our report looks into how managers are ranked for their own abilities and then comparing this to how managers are ranked from an employee’s perspective. To do this we spoke to 150 managers and 150 employees to cover specific areas and from this we’ve picked up on the following results:
- Only 53% of managers in the digital sector ranked their own abilities as ‘good’, ‘really good’, or ‘excellent’, with the rest ranking their abilities as ‘average’ or ‘below average’ – suggesting a lack of confidence in their managerial skills
- Good communication is the quality that both managers and employees working in digital cited as the most important. Approachability was highly valued by 46% of employees, but just 24% of managers agreed
- 27% of employees cited that being highly skilled, was a in the top 3 qualities of being a manger
- Surprisingly 3% of employees started that having a bad manager would have no effect on the team whereas every manager agreed that being a bad manager would affect the whole team
Our very own Brian Matthews states why this research is important for the development of the industry.
‘The industry now employs 1.46m people across the country, and is estimated to grow by 5.4% by 2020. In order to develop the industry successfully and help it grow at its expected pace, we need the help of good managers who can nature the talent’
We’re hoping that our report helps to reveal some issues which may have an effect on the digital sector.
For the full video of this presentation, please visit:
http://www.embedded-vision.com/industry-analysis/video-interviews-demos/overcoming-barriers-consumer-adoption-vision-enabled-produc
For more information about embedded vision, please visit:
http://www.embedded-vision.com
John Feland, CEO and Founder of Argus Insights, presents the "Overcoming Barriers to Consumer Adoption of Vision-enabled Products and Services" tutorial at the May 2015 Embedded Vision Summit.
Visual intelligence is being deployed in a growing range of consumer products, including smartphones, tablets, security cameras, laptops (especially with Intel’s RealSense push), and even smartwatches. The demos are always cool. But does vision work for regular consumers? Do consumers see vision as a value add or just another feature to be ignored?
In this talk, John investigates the best and worst of consumer product embedded vision implementations as told by real consumers, based on Argus Insights’ extensive portfolio of consumer data. John examines where current products fall short of consumers’ needs. And, he illuminates successful implementations to show how their vision capabilities create value in the lives of consumers. Case studies will include examples from Dropcam, Intel RealSense, HTC’s M8, and vision-enabled drones such as the DJI Phantom 2 Vision+.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
The new role of R&D and process for new products in pharmaceutical industry has been established
Productivity increase of Orion R&D within 6 years by :
-Classification of partners
-Partnering and outsourcing models in use
Need of reliable key metrics to value R&D investment and boost the future growth of the company
In silico 360 Analysis for Drug DevelopmentChris Southan
Introduction:
Consequent to a memorandum of understanding between the Karolinska Institutet and the International Union of Basic and Clinical Pharmacology (IUPHAR) in 2018 a report on academic drug development, including guidelines (ADEV) has been drafted [1]. As part of this exercise, we conceived a triage for comprehensive informatics profiling around the compound, target, disease axis. We have termed this “in slico 360” (INS360) the aim of which was to support ADEV teams since they may lack either internal expertise or external support to do this on their own. Indeed, some past SciLifeLab Drug Discovery and Development Platform projects had been halted because of overlooked competitive impingements or insufficient target validation evidence.
Methods
We assessed the current database landscape, mostly public but including commercial, for potential utility for INS360. We were guided primarily by content coverage, usability, and reputation. We also explored some open property prediction resources for assay interference and toxicological inferences.
Results:
As a first-stop-shop, we selected the IUPHAR/BPS Guide to PHARMACOLOGY with ~900 ligand-target relationships captured via expert curation of journal papers Moving up in scale we evaluated ChEMBL at 1.8 million compounds with 1.1 million assay descriptions and 7,000 targets. With yet another jump we could search the patent corpus with 18 million extracted compounds in SureChEMBL. We explored PubChem that integrates these three with over 500 other sources linked to 96 million compounds, BioAssay results and connectivity into the NCBI Entrez system. The final jump in scale for document-to-chemistry navigation was represented by SciFinder with 155 million structures. On the target side, 360-exploration has the need to encompass literature, structure, genetic variation, splicing, interactions, and disease pathways. From their UniProt links, both GtoPdb and ChEMBL provide these entry points. Navigating genetic association data in support of target validation was enabled by the OpenTargets portal and the GWAS Catalog. We also fount servers that could produce prediction scores from chemical structures for a range of features important for de-risking development.
Conclusion:
This work scoped out initial resource choices for the INS360. We propose that not only ADEV operations but essentially any pharmacology research team has much to gain from this approach and many potential pitfalls can consequently be avoided when approaching key checkpoints, such as preparing a publication. However, support may be needed for both institutions and teams to get the best out of these complex and feature-rich databases.
[1] Southan C, (2019) Towards Academic Drug Development Guidelines, ChemRxiv pre-print no. 8869574
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryJean-Claude Bradley
Mel Reichman, senior investigator and director of the LIMR Chemical Genomics Center at the Lankenau Institute for Medical Research presents at the chemistry department at Drexel University on November 12, 2009.
Modern drug discovery by high-throughput screening (HTS) begins with testing hundreds of thousands of compounds in biological assays. The confirmed hit rate for typical HTS is less than 0.5%; therefore, 99.5% of the costs of HTS are for generating null data. Orthogonal convolution of compound libraries (OCL) is 500% more efficient than present HTS practice. The OCL method combines 10 compounds per well. An advantage of this method is that each compound is represented twice in two separately arrayed pools. The potential for the approach to better enable academic centers of excellence to validate medicinally relevant biological targets is discussed.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Osp 1st sep2015 OSDD
1. Open Source Drug Discovery
OSDD
www.osdd.net
Geetha Vani Rayasam
Principal Scientist
2. The Open Innovation Model : OSDD strategy
• Porous-walled funnel facilitates free flow of ideas / projects
• Bring in more eyeballs to look at the inside
• Enables Redundancies and Parallelization
Fuzzy Front-End Research DevelopmentInputs
INTEGRATED
OSDD PROJECT
Inputs
Platforms driving the
process
Technology
Hits / Lead Molecules
Image Source: Clorox, Andy Gilinkski,
www.imaginatik.com
OSDD
OSDD
INDIVIDUAL PIs
IDEAS
Marrying The TWO CULTURES
- Academic
- Delivery focused
- OSDD THE FACILITATOR
OSDD the leader
- Expertise
- Discovery Platforms
GLOBALISING
THE EFFORT
New Combination
GATB
6. OSDD: Coordination of Activities
Bottom Up
Top Down
Individual Driven
Volunteer contributions
Progression of target based & ligand
based approaches
Contribution of resources and skills
Community Developed Projects
Crowd sourcing for solving challenges
(genome annotation for systems level
understanding)
Streamlining processes & resources
(repositories/computational resources)
Focused effort to targeted deliverables
(CROs & Academic Collaborations)
Centrally Coordinated Projects
8. Crowdsourcing
MPDSTB
Phase I
2009
Phase II
2010
Phase II
2011
Phase III
2013-14
Chem-
informatics
Phase II
2012-13
Genome Annotation for Drug
Target Identification through
Systems Level Analysis
Cloning of predicted targets &
cheminformatics to predict
potential inhibitors
Identify target-specific filters;
Establish Molecular Property
Diagnostic Suite
9. Current status
No. of PIs: 84 (88 projects)
Current library strength: 10000
Compounds screened: 8500
Scaffolds prioritized: 11
Compounds screened against malarial
parasite
• 16 primary hits
Chemically Diverse Compounds
N
N
O
O
N
N
O
N
N
N
N
N
N
Cl
N
N
OH
O
H2N
NCL: Carbohydrate Chemistry
CLRI: Heterocyclic Chemistry
IICT: Peptide & Natural Product Chemistry
NIIST: Natural Product Chemistry
NEIST: Heterocyclic Chemistry
IIIM: Medicinal chemistry
CDRI: Medicinal and Scale up Chemistry
Distribution of Chemistry PIs across India
Cl
O
S
N
N
N
OSDD’s Chemistry approach for TB drug discovery
10. Figure 2. General structures of proposed molecules 7, 8 and 9
N
N S
O
R1
R2
R
R=Heterocycl, alkyl, aryl, alkenyl,
OH, OR3
, COOR4
, CONR5
R6
etc,
R1
, R2
= H, subst alkyl, subst aryl
N
N S
O
X
R1
R2
N
R= subst alkyl, subst aryl,
CH2OH, CH2OR3
, COOR4
etc,
R1
, R2
= H, subst alkyl, subst aryl
X= (CH2)n
N N
R
R= subst alkyl, subst aryl,
CH2OH, CH2OR3
, COOR4
etc,
R1
, R2
= H, subst alkyl, subst aryl
X= (CH2)n
N
N S
O
X
R1
R2
N
N
N
R
6
7 8
Figure 3. General structures of proposed molecules 9 and 10
N
H
S
R1
R2
R= CN, COOR4, CONR5R6 etc,
R1
, R2
= H, subst alkyl, subst aryl
R3
= subst alkyl, subst aryl
R,R', R3= H, subst alkyl, subst aryl
R1
, R2
= H, subst alkyl, subst aryl
R4= subst alkyl, subst aryl
9 10
R
R3
O
N S
R1
R2
N
N N
R4
R3
R'RN
O
Project Proposal (Dr. Borate, NCL)
i. Prioritize thienopyrimidines
ii. thiourea, thiocarbamate, hydrazide, pyridyl amine, phenyl
amine etc may be avoided from the point of toxicity
iii. Dicyanoanilines need to be removed
iv. R, R1, R2 may be independently chosen from aryl, heteroaryl,
CONH2, SO2NHR’, OH and a chain containing OH, OR and NHR
groups. Restrict to only one or two aromatic/heteroaromatic
rings
1 32 4 5
Compounds synthesized
N
N S
R
O
R1
Project Formulation
i. This is an example describes how projects are formulated
ii. Scientific inputs are provided to all chemistry projects
12. Bridging the Gap in Drug Discovery: CDRI-830 Project
Around 150
analogues,
MIC on M. tb.
Trisubstituted methanes
(CDRI-830)
H, Alkoxy, S-alkyl,
F, Cl, in o, m and
p positions. P-
MeO and p-F are
the most potent.
Phenyl, naphthyl,
pyridyl, indolyl,
pyrrolys
Only naphthyl is better
tolerated
Many open chain
and cyclic groups.
Only diisopropyl is
better tolerated.
No substitutions
tried on ring B
New CDRI 830 Fragment OSDD-29
Identified
~ 300 compounds Designed and
synthesized by OSDD and Jubilant
SAR
SAR
Several potent ‘hits’ identified
(<1 ug/ml)
13. OSDD Model of Translating Academic Research into Drug
Discovery Projects
Identify
Potential
Academic
Projects
Work with the
PI in building
the discovery
project
Bring in additional
complementary academic
partners
Strong Drug
Discovery Project
with clear
deliverables and
time linesContract Research
Organizations to fills the
gaps in drug discovery
OSDD Drug Discovery
Experts Inputs
14. Translating Academic Research into Drug Discovery Dap A/B Project
0
0.2
0.4
0.6
0.8
0 5 10 15 20
Absorbanceat334nm
Time in Min.
Low throughput
Assay
DapA/DapB:
Cloning/expression
/purification
Random Screening of
3500 compounds
IC50s of hundreds of
compounds
ChemoInformatics
Identify new
libraries
Validate the ‘hits’
Secondary ‘binding assays’
Orthogonal assays: HPLC/LC-MS
0
0.1
0.2
0.3
0.4
0.5
0.6
0 10 20 30 40 50 60
OD334nM
Time in mins
High Throughput Assay
Structure-based Strategy
Project Driven By OSDD
• Intellectual input
• Bringing in Partners: Anthem
0%
20%
40%
60%
80%
0 200 400 600
%Inhibition
Compound (µM)
0-10
0-20
0-30
0-40
0-50
0-60
a Keto Pimelate
an inhibitor of DapA/B
15. OSDD-TB Alliance Phase IIb Clinical Trial
In MDR Tuberculosis Patients
To evaluate the anti-mycobacterial activity, safety, tolerability and
pharmcokinetics of drugs/regimens under evaluation
• Trial Center: LRS Institute of Tuberculosis (a tertiary care hospital)
• Trial Size: ~80 patients in each arm
Recruitment has been initiated
Trial data to be made open without comprising patient confidentiality
Pa+ Cat IV regimen 2 months of treatment
Cat IV regimen
Pa-M-Z
Cat IV treatment
Pa = PA-824;
M = moxifloxacin;
Z = pyrazinamide
Hospitalization
16. •Central storage and distribution
center (CDRI and MolBank @ IICT)
•Open database (OSDD ChemDesign)
•Target validation with knockout &
knockdown in M.smeg and M.tb
and clinical strains (Premas Biotech)
•Cloning, expression & purification of
targets. (Sastra University, CSIR labs,
and Anthem)
•Assay development and
optimization (Labs and Anthem)
•High throughput biochemical
screening (Anthem)
•Whole-cell screening
M.smeg (IICT)
M.tb (CDRI, IIIM, IGIB & Premas
Biotech)
Malaria (CDRI)
•Toxicity in mammalian cells (IICT)
•Generation of compound-resistant
mutants (CDRI)
•Whole genome sequencing (IGIB
and CROs)
Platforms Currently Established
Mechanism
of Action
ScreeningBiology
Compound
Management
17. Screening Hit to Lead
Whole Cell based Target based
• Screening of 20,000 drug like compounds:
analysis and prioritize new scaffolds (CSIR-
IIIM)
• Screening of 30,000 compounds, in replicating
and non replicating Mtb (CSIR-IIIM)
• Screening of 30,000 compounds (CSIR-CDRI)
• Screening of 10,000 compounds (CSIR-IICT)
Directed Chemistry Synthesis at CSIR
Labs: 60 projects
IICT/NCL/NIIST/NEIST/CLRI
• OSDDChem: > 20 projects from various
institutes and universities; screening in parallel
against TB and malaria (CSIR-CDRI)
• Plant derived anti-Infective library (1000) of
pure compounds (Premas Biotech)
• Identification of anti-mycobacterial molecules
from Actinomycetes (RGCB)
• GlmU: Development of inhibitors through
structure based drug design (NII/BITS-Hyd/IIT-K)
• Dap A/B: Identification of new inhibitors (CSIR-
IGIB/Anthem Biosciences)
• Structure-activity relationship study of NAD
Dependent LigA inhibitors (CSIR-CDRI)
• Disruption of Sigma Factors-RNA polymerase
interaction to target Mtb (OSDD Unit/IISc)
• Investigation on bioactive molecules inhibiting
betalactamases and MAP of Mtb (CSIR-NIIST)
• Identification of inhibitors targeting Mur pathway
(ANDC)
• The role of dos regulon proteins of Mtb in
persistence (Univ of Hyderabad)
• Phage based therapy for TB (Ganagen)
• Ribosome Biogenesis (IIT-K)
• Inhibitors of Type 7 secretion (OSDD & Univ of
Umea, Sweden)
• CDRI-SOO6-830: SAR
analysis, initial PK, MOA
studies (CSIR-CDRI /
Jubilant Chemsys)
• LAMS (CSIR-IGIB /CSIR-
NCL/Jubilant Chemsys):
Identifying new
chemotypes & single target
vs. multi target
• Optimization of ‘hits’ from
whole cell based screening
for TB (CSIR labs &
Jubilant Chemsys)
OSDD Discovery Portfolio for TB
Other Projects: Resources/New Concepts/Diagnostics/Pharmacogenomics/Mtb
genome sequencing
More than 180 PIs from over 100 institutions contributing to the portfolio
18. Long Term Commitment and Sustained Support
to the Philosophy and Program
• patents/royalty/pricing/licensing
Risk taking ability
Partnering with Industry
Key Learning in Implementation of Drug
Discovery Program in an Open Source Setting
Slide 1 of 4
19. Key Learning in Implementation of Drug
Discovery Program in an Open Source Setting
Slide 2 of 4
Working with compounds/regimens developed
outside India
Obtaining regulatory clearances for clinical
trials
Incorporation of approved drugs into the
national program
20. Slide 3 of 4
Key Learning in Implementation of Drug
Discovery Program in an Open Source Setting
Leadership and Implementing Team
Building trust and confidence in the model, in sharing
data and in the executing team
What drives the collaborations?? Academics..
• Provide value to the contributors
Transparent decision making
Transparent credit sharing
21. Engaging multiple national and international stakeholders and
financing them
Faster and efficient delivery of funds
Hiring and retaining technical experts from Industry
Funding Crowd Sourcing activities
Engaging and delivery from CROs
Key Learning in Implementation of Drug Discovery
Program in an Open Source Setting
Slide 4 of 4
22. Synergy Between Different Players
Affordable
Drugs for
Neglected
Diseases
PDPs
Clinical Development
Government
Agencies
Discovery
Clinical Trials &
Implementation
Not for Profit
Pre-clinical
Development
Industry Collaboration
Crowd Sourcing
Proof of Concept to be established on Success for Open Source Philosophy in
Affordability of drugs and Increased rates of Success
Complement Not Compete
23. Suggestions for OSP
Vision &
Mission
5 years
Outputs
Outcomes
10 years
Outputs
Outcomes
Break Up into Yearly Actionable Milestones/Deliverables
24. Together we can …
.. and we should !
Matt Smadley | Flickr.com
http://www.osdd.net
http://c2d.osdd.net
http://sysborg2.osdd.net
http://crdd.osdd.net/osddchem/index.html
Email: info@osdd.net
Dr Sarala Balachandran: Project Director & Clinical Trials
Dr Anshu Bhardwaj: Predictive Sciences & Crowd Sourcing Expert
Prof SK Brahmachari
Dr T Balganesh
Zakir Thomas
Dr Haridas Rode
Dr B. Ugarkar
Dr Jaleel
Principal Investigators, Consultants, Students
CROs, Collaborators, OSDD Community…….